- Home
- KE vs RGNX Comparison
KE vs RGNX Comparison
Compare KE & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KE
- RGNX
- Stock Information
- Founded
- KE 1961
- RGNX 2008
- Country
- KE United States
- RGNX United States
- Employees
- KE N/A
- RGNX N/A
- Industry
- KE Electrical Products
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KE Technology
- RGNX Health Care
- Exchange
- KE Nasdaq
- RGNX Nasdaq
- Market Cap
- KE 495.6M
- RGNX 459.1M
- IPO Year
- KE N/A
- RGNX 2015
- Fundamental
- Price
- KE $19.74
- RGNX $9.30
- Analyst Decision
- KE Buy
- RGNX Strong Buy
- Analyst Count
- KE 5
- RGNX 12
- Target Price
- KE $22.60
- RGNX $36.36
- AVG Volume (30 Days)
- KE 115.8K
- RGNX 968.2K
- Earning Date
- KE 02-03-2025
- RGNX 11-06-2024
- Dividend Yield
- KE N/A
- RGNX N/A
- EPS Growth
- KE N/A
- RGNX N/A
- EPS
- KE 0.50
- RGNX N/A
- Revenue
- KE $1,650,685,000.00
- RGNX $84,327,000.00
- Revenue This Year
- KE N/A
- RGNX $2.34
- Revenue Next Year
- KE $4.18
- RGNX $243.67
- P/E Ratio
- KE $39.56
- RGNX N/A
- Revenue Growth
- KE N/A
- RGNX N/A
- 52 Week Low
- KE $16.64
- RGNX $8.54
- 52 Week High
- KE $27.73
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- KE 54.39
- RGNX 44.04
- Support Level
- KE $19.28
- RGNX $9.39
- Resistance Level
- KE $20.47
- RGNX $10.39
- Average True Range (ATR)
- KE 0.59
- RGNX 0.87
- MACD
- KE -0.02
- RGNX -0.02
- Stochastic Oscillator
- KE 60.80
- RGNX 13.41
About KE Kimball Electronics Inc.
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it derives a majority of revenue from the United States.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.